Duloxetine for PHN

NACompletedINTERVENTIONAL
Enrollment

750

Participants

Timeline

Start Date

March 1, 2021

Primary Completion Date

May 16, 2023

Study Completion Date

May 16, 2023

Conditions
Postherpetic Neuralgia
Interventions
DRUG

Duloxetine

Oral Duloxetine (up to 60 mg per day) will be given, titrated, tapered in accordance with the pain intensity during the acute herpes zoster period.

Trial Locations (1)

100050

Beijing Tiantan Hospital, Beijing

All Listed Sponsors
collaborator

China-Japan Friendship Hospital

OTHER

collaborator

Tianjin Medical University Second Hospital

OTHER

collaborator

Taiyuan Central Hospital of Shanxi Medical University

OTHER

collaborator

Linfen Fourth People's Hospital

UNKNOWN

collaborator

Shandong Provincial Hospital

OTHER_GOV

collaborator

Qingdao Municipal Hospital (Group)

UNKNOWN

collaborator

The Second People's Hospital of Huai'an

OTHER

collaborator

First Hospital of China Medical University

OTHER

collaborator

Second Affiliated Hospital of Zhengzhou University

OTHER

collaborator

Fujian Provincial Hospital

OTHER

collaborator

Cangzhou Central Hospital

OTHER

collaborator

The People's Hospital of Fujian Province

UNKNOWN

collaborator

Beijing Tsinghua Chang Gung Hospital

OTHER

collaborator

Peking University International Hospital

OTHER

collaborator

Tianjin First Central Hospital

OTHER

collaborator

Tianjin Huanhu Hospital

OTHER

collaborator

Baoding First Central Hospital

OTHER

lead

Beijing Tiantan Hospital

OTHER

NCT04313335 - Duloxetine for PHN | Biotech Hunter | Biotech Hunter